Vor Biopharma Inc (VOR)

$1.96 +0.03 (1.55%)
Market Cap 248.30M
Revenue (ttm) 0.00
Net Income (ttm) -116.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,059,500
Avg Vol 16,483,674
Day's Range N/A - N/A
Shares Out 126.68M
Stochastic %K 10%
Beta 2.05
Analysts Hold
Price Target $1.18

Company Profile

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 655 6580
Address:
100 Cambridgepark Drive, Suite 101, Cambridge, United States
Micabella
Micabella Sep. 5 at 12:43 AM
$VOR Reid Hoffman sold all holdings. Good enough for me . I'm out GLTL
1 · Reply
Sswerve
Sswerve Sep. 3 at 4:51 PM
$VOR It's still trading at $2 lmao. Nasdaq needs to do something about these zombie companies
0 · Reply
Lohengrin72
Lohengrin72 Sep. 3 at 1:42 PM
$VOR in case you have questions about the new asset: https://ir.vorbio.com/static-files/cd8093d1-fc39-45f3-ac8d-621c296b1a46
1 · Reply
Mr_GA
Mr_GA Sep. 2 at 4:22 PM
$VOR https://finance.yahoo.com/news/vor-bio-appoints-adi-osovsky-120000267.html
0 · Reply
Mr_GA
Mr_GA Sep. 2 at 2:22 AM
$VOR
0 · Reply
Sswerve
Sswerve Sep. 1 at 12:43 AM
$VOR This shady LLC was given 38 million in stock for $0 at the start of the year , they already sold 4.2 million worth last week. Free money created out of thin air on the backs of retail. Also nice touch for them to have filings come out in AH on friday. This is top you bulls are nothing but exit liquidity. Watch and see there will be more insider sales they know the rug pull is on the way. https://ir.vorbio.com/static-files/a80d13f2-2233-423e-8d19-0a11202fa667
1 · Reply
Mr_GA
Mr_GA Aug. 31 at 2:58 AM
$VOR I don't know if many here are aware that VOR founder Dr. Siddhartha Mukherjee and Reid Hoffman (LinkedIn co-founder, and other ventures, including being involved with VOR) founded Manas AI earlier this year. Manas AI is a private company. VOR has been hiring some talented management type people recently, especially the new CEO Jean-Paul Kress. There seems to be a lot going on behind the scenes that we are not privvy to (IMO). Is it a possibility that Manas AI is going to reverse merge with VOR in order to take Manas AI public? manasai.co
0 · Reply
Jesusrey
Jesusrey Aug. 29 at 11:15 PM
$VOR Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: Reprogrammed Interchange LLC 10K WIZARD 5:31 PM ET 8/29/2025 http://archive.fast-edgar.com/20250829/A8L2U22CKM22S2Z3222E2WZZRSWPA2S2Z272 Filed on: August 29, 2025
1 · Reply
deerix
deerix Aug. 29 at 10:37 AM
$TLRY How much do I have to prove myself before people start following me instead of a bunch of braindead pumpers. I am always very transparent about every move I make in these markets. ➡️ VIEW PINNED POST ON PROFILE ✅️ Did 1000% on $OPEN and 1400% on $VOR Like any pro, I win some, I lose some. But oh God, have I been on a crazy run so far!
5 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Aug. 28 at 11:59 AM
$RAYA $IXHL $VOR $KLTO $THAR
0 · Reply
Latest News on VOR
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Sep 2, 2025, 8:00 AM EDT - 5 days ago

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Aug 27, 2025, 8:00 AM EDT - 11 days ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Vor Bio to Participate in Upcoming Investor Conferences

Aug 26, 2025, 8:00 AM EDT - 12 days ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 18, 2025, 4:35 PM EDT - 20 days ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Aug 13, 2025, 11:15 AM EDT - 25 days ago

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Aug 13, 2025, 8:30 AM EDT - 25 days ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Aug 4, 2025, 8:30 AM EDT - 4 weeks ago

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 21, 2025, 8:30 AM EDT - 6 weeks ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 18, 2025, 4:00 PM EDT - 7 weeks ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 17, 2025, 8:30 AM EDT - 7 weeks ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 10, 2025, 4:00 PM EDT - 2 months ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 4:00 PM EDT - 2 months ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Jun 30, 2025, 2:31 PM EDT - 2 months ago

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:50 PM EDT - 2 months ago

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Jun 25, 2025, 4:45 PM EDT - 2 months ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025, 8:30 AM EDT - 4 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Mar 20, 2025, 4:05 PM EDT - 6 months ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 13, 2025, 8:00 AM EST - 7 months ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 7 months ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Jan 8, 2025, 9:00 AM EST - 8 months ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Bio Announces $55.6 Million Private Placement

Dec 27, 2024, 9:00 AM EST - 9 months ago

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Dec 9, 2024, 7:30 AM EST - 9 months ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 6, 2024, 9:35 AM EDT - 1 year ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Sep 5, 2024, 4:01 PM EDT - 1 year ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Jan 17, 2024, 4:01 PM EST - 1 year ago

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Nov 27, 2023, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Nov 9, 2023, 4:01 PM EST - 1 year ago

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 7, 2023, 4:05 PM EST - 1 year ago

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Nov 2, 2023, 9:01 AM EDT - 2 years ago

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

Jul 5, 2023, 8:51 AM EDT - 2 years ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

CBUS LUCY

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Jun 9, 2023, 7:30 AM EDT - 2 years ago

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Mar 27, 2023, 3:13 PM EDT - 2 years ago

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Feb 16, 2023, 12:00 PM EST - 2 years ago

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Jan 19, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

Jan 12, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

Dec 7, 2022, 7:45 AM EST - 2 years ago

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Dec 7, 2022, 7:30 AM EST - 2 years ago

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Nov 10, 2022, 4:15 PM EST - 3 years ago

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Vor Bio Appoints Eyal C. Attar, M.D.

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Appoints Eyal C. Attar, M.D.

Micabella
Micabella Sep. 5 at 12:43 AM
$VOR Reid Hoffman sold all holdings. Good enough for me . I'm out GLTL
1 · Reply
Sswerve
Sswerve Sep. 3 at 4:51 PM
$VOR It's still trading at $2 lmao. Nasdaq needs to do something about these zombie companies
0 · Reply
Lohengrin72
Lohengrin72 Sep. 3 at 1:42 PM
$VOR in case you have questions about the new asset: https://ir.vorbio.com/static-files/cd8093d1-fc39-45f3-ac8d-621c296b1a46
1 · Reply
Mr_GA
Mr_GA Sep. 2 at 4:22 PM
$VOR https://finance.yahoo.com/news/vor-bio-appoints-adi-osovsky-120000267.html
0 · Reply
Mr_GA
Mr_GA Sep. 2 at 2:22 AM
$VOR
0 · Reply
Sswerve
Sswerve Sep. 1 at 12:43 AM
$VOR This shady LLC was given 38 million in stock for $0 at the start of the year , they already sold 4.2 million worth last week. Free money created out of thin air on the backs of retail. Also nice touch for them to have filings come out in AH on friday. This is top you bulls are nothing but exit liquidity. Watch and see there will be more insider sales they know the rug pull is on the way. https://ir.vorbio.com/static-files/a80d13f2-2233-423e-8d19-0a11202fa667
1 · Reply
Mr_GA
Mr_GA Aug. 31 at 2:58 AM
$VOR I don't know if many here are aware that VOR founder Dr. Siddhartha Mukherjee and Reid Hoffman (LinkedIn co-founder, and other ventures, including being involved with VOR) founded Manas AI earlier this year. Manas AI is a private company. VOR has been hiring some talented management type people recently, especially the new CEO Jean-Paul Kress. There seems to be a lot going on behind the scenes that we are not privvy to (IMO). Is it a possibility that Manas AI is going to reverse merge with VOR in order to take Manas AI public? manasai.co
0 · Reply
Jesusrey
Jesusrey Aug. 29 at 11:15 PM
$VOR Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: Reprogrammed Interchange LLC 10K WIZARD 5:31 PM ET 8/29/2025 http://archive.fast-edgar.com/20250829/A8L2U22CKM22S2Z3222E2WZZRSWPA2S2Z272 Filed on: August 29, 2025
1 · Reply
deerix
deerix Aug. 29 at 10:37 AM
$TLRY How much do I have to prove myself before people start following me instead of a bunch of braindead pumpers. I am always very transparent about every move I make in these markets. ➡️ VIEW PINNED POST ON PROFILE ✅️ Did 1000% on $OPEN and 1400% on $VOR Like any pro, I win some, I lose some. But oh God, have I been on a crazy run so far!
5 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Aug. 28 at 11:59 AM
$RAYA $IXHL $VOR $KLTO $THAR
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Aug. 28 at 9:13 AM
$RAYA $0.10 exploding. $3.35 last run. shares maxed out. no rs before september 8th meeting. will be huge like my other epic calls : $IXHL 0.08 - 1.73 $VOR 0.13 - 3.29 $KLTO 0.19 - 3.91 $THAR 1.38 - 9.08
1 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Aug. 28 at 8:35 AM
$RAYA $0.10 reminds me of $VOR my call at $0.13 hit $3.29
0 · Reply
Micabella
Micabella Aug. 28 at 1:26 AM
$VOR What me worry? with RA Capital and Reid Hoffman owning 50% of the company, why should I worry about dilution. Somehow I think they have figured this out
2 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 27 at 5:24 PM
$VOR Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
1 · Reply
Sswerve
Sswerve Aug. 27 at 3:49 PM
$VOR Dead money until dilution, MM will keep this around $2. No upside and extreme downside whenever those shares are exercised
1 · Reply
rambo222
rambo222 Aug. 27 at 2:07 PM
$VOR Got to love when good news brings the price down. Opposite world now that shorting is entrenched in the markets.
1 · Reply
Teo_j
Teo_j Aug. 27 at 12:51 PM
$VOR
0 · Reply
stockmando
stockmando Aug. 27 at 12:29 PM
$VOR just filed $119M USD atm via Stifel
1 · Reply
OpenOutcrier
OpenOutcrier Aug. 27 at 12:24 PM
$VOR (+2.9% pre) Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy https://ooc.bz/l/75330
1 · Reply
Zkillerz323
Zkillerz323 Aug. 27 at 12:08 PM
$VOR https://www.stocktitan.net/news/VOR/telitacicept-achieved-primary-endpoint-in-phase-3-clinical-study-for-y5pl5qiv9htw.html
1 · Reply
Stock_Catcher
Stock_Catcher Aug. 27 at 2:02 AM
Winner Wednesday Watchlist Pt.17 $CORZ $ADMA $NCNA $HCTI $VOR Let's Have a Great Day Tomorrow 🌞
1 · Reply
CalculatedSwing
CalculatedSwing Aug. 26 at 11:56 AM
$GLMD $GLMD Eyes on the horizon! With $15.7M cash & no debt, Galmed’s pivoting smart—$10M into digital assets could be a game-changer. ARMOR study’s open-label success (anti-fibrotic wins in 2022/24) hints at a 2026 approval shot, even with the double-blind pause. Termination of the Entomus deal opens new doors—minority stake move might spark partnerships. Down 27% this month, but low float & NASH potential could fuel a rebound. Watch for Q3 updates! #biotech #NASH #investing $VOR
0 · Reply